Which medications in the drug class Antiplatelet Agents, Hematologic are used in the treatment of Takayasu Arteritis?

Updated: Nov 14, 2018
  • Author: Jefferson R Roberts, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Antiplatelet Agents, Hematologic

These drugs help to prevent cerebrovascular accidents and improve renal and systemic function.

Ticlopidine hydrochloride

Ticlopidine hydrochloride interferes with platelet membrane function by inhibiting adenosine diphosphate (ADP) ̶ induced platelet-fibrinogen binding and subsequent platelet-platelet interaction. It is used as a second-line antiplatelet therapy for patients who are intolerant to aspirin therapy or in whom such therapy fails.

Clopidogrel (Plavix)

Clopidogrel is a thienopyridine derivative chemically related to ticlopidine that inhibits platelet aggregation; it selectively inhibits ADP binding to its platelet receptor and subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.

Aspirin and extended-release dipyridamole (Aggrenox)

This drug combination has antithrombotic action. Aspirin inhibits prostaglandin synthesis, preventing the formation of platelet-aggregating thromboxane A2. It may be used in low dose to inhibit platelet aggregation and improve complications of venous stases and thrombosis.

Dipyridamole is a platelet adhesion inhibitor that possibly inhibits red blood cell uptake of adenosine, itself an inhibitor of platelet reactivity. In addition, dipyridamole may inhibit phosphodiesterase activity leading to increased cyclic-3', 5'-adenosine monophosphate within platelets and formation of the potent platelet activator thromboxane A2.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!